Purpose: To evaluate the efficacy and tolerability of the ketogenic diet (KD) as a treatment for drugresistant epilepsy secondary to malformations of cortical development. Methods: A two-centre retrospective analysis of 45 paediatric patients with refractory epilepsy due to malformation of cortical development was carried out. Patients were divided into three groups based on malformation type: abnormal neural proliferation (Group 1); abnormal neural migration (Group 2) and abnormal post-migrational development (Group 3). The efficacy of the KD was assessed in terms of seizure frequency reduction. We identified the proportion of patients achieving > 50% seizure frequency reduction overall and in the three subgroups. Results: The adherence to KD was variable. KD was pursued from a minimum of 4 months to a maximum of 96 months. 20 patients (44%) obtained a seizure reduction of > 50% and 2 patients became seizure free. >50% seizure reduction was most commonly achieved by patients in group 3 (64.7%) than in groups 2 (31.8%) and 1 (33.3%). Conclusions: The best response was observed in patients with malformations of post migrational development. Considering its tolerability, the use of KD should be considered in patients with drugresistant epilepsy secondary to malformations of cortical development when surgery is not a viable option.
Introduction
The ketogenic diet (KD) is an established non-pharmacological treatment for drug-resistant epilepsy (DRE). The precise incidence of malformations of cortical development (MCDs) is not known, however it is estimated that 25% to 40% of intractable childhood epilepsy is attributable to MCDs, and that at least 75% of patients with MCDs will have epilepsy [1] .
The usefulness of KD in epileptic patients with MCD has not been widely described in literature. When surgery is a viable option, it should be favored over a KD. As underlined by Stainman et al. [2] , children with surgically approachable epilepsy do respond to the diet but are more likely to be seizure-free following surgery. The purpose of this study is to describe the use of KD in a series of patients with DRE with MCD unsuitable for surgery and to consider whether there is a malformation type that best responds to KD.
Subjects and methods
We present herein a two-centre retrospective study including 45 patients with a mean age of 49 AE 41, 60 AE 35, 74 AE 32 months for group 1,2,3 respectively (range 9-157 months), with DRE due to MCD, treated with KD at National Neurological Institute C. Mondino, Pavia (Italy), and Prof. Juan Garrahan Hospital, Buenos Aires (Argentina), between 1994 and 2015.
Patients enrolled in our study had epilepsy refractory to antiepileptic drugs (AEDs) and were diagnosed with Lennox Gastaut Syndrome (LGS), Electrical Status Epilepticus during Sleep (ESES), and childhood epileptic encephalopathy. All patients underwent magnetic resonance imaging (MRI) in order to classify the cortical malformation.
All patients were treated with specific pharmacotherapy. At the time of enrollment, 31 patients had daily seizures, 11 patients had weekly seizures and 3 patients had sporadic seizures.
Seizure types and epilepsy syndromes were classified according to the criteria proposed by the International League Against Epilepsy (ILAE). Patients were divided according to the etiological classification of malformations of cortical development by Barkovich et al. [3] . Six patients had malformations of abnormal neural proliferation (diffuse cortical dysplasia, microlissencephaly and hemimegalencephaly) (group 1), 22 patients had malformations of abnormal neural migration (nodular heterotopia, double cortex, band heterotopia, pachygyria-agyria, lissencephaly) (group 2), and 17 patients had malformations of abnormal postmigrational development (polymicrogyria (unilateral or bilateral), focal cortical dysplasia unsuitable for surgery (multiple or surgical inaccessibility), and schizencephaly) (group 3) ( Table 1 ).
In the group of patients with malformations of abnormal neural proliferation, the mean age of patients starting the diet was 49 months, earlier than the other 2 groups (60 and 74 months respectively). Likewise, the meantime interval between seizure onset and KD initiation was 22.5 months in the group of malformations of abnormal neural proliferation and 30 and 48 months in the other two groups ( Table 1) .
The Italian (Veggiotti et al,) [4] and Argentinian (Armeno et al,) [5] consensus were used for KD titration and patient management. All patients underwent classical 4:1 or 3:1 lipid to protein ratio.
Regular follow-up, including assessment of neurological status, seizure frequency, nutritional status, compliance and diet evaluations were carried at 3 to 6 month intervals. Anti-epileptic drugs (AEDs) were continued and titrated during the KD.
Results
The adherence to KD was variable with a minimum of 4 months and a maximum of 96 months (median follow-up 32, 21 and 27 months for group 1,2,3 respectively).
The results are shown in consideration of the overall population and splitting it into three groups. Patients were divided into responders (seizure reduction > 50%) and non-responders (seizure reduction < 50%) and had different follow-up, as described in the method section.
The responders (seizure reduction of 50% or higher) experienced the beneficial effects of KD after just three months. We carried out a Chi-square test: despite the fact that no statistical significance was found, a positive trend suggested a better response to treatment in patients from group 3 than in the other two groups.
At the time of last follow-up, 20 patients (44%) obtained a seizure reduction of > 50% and 2 patients were seizure free. The patients in group 3 had the highest rate of seizure reduction: 11 (64.7%) patients having a seizure reduction of > 50%, one patient being seizure free and 3 patients (17.6%) showing a seizure reduction of <50%.In group 2, 7 patients (31.8%) experienced a seizure reduction of > 50% and 12 patients (54.6%) displayed a seizure reduction of < 50%. Finally,in group 1, 2 patients (33.3%) attained > 50% seizure reduction, 1 patient obtained seizure freedom (16.7%) and only 1 patient (16.7%) had a < 50% seizure reduction (Table 2) .
Thirty-six patients (80%) continued KD for more than one year. Reasons for early diet discontinuation (< 12 months) were: inefficacy in 6 patients, gastrointestinal (GI) side effects in 1 patient and poor compliance in 1 patient.
Other causes of discontinuation (after 12 months) were: decreased seizure control in 10 patients, poor compliance in 6 patients and GI side effects in 1 patient. 19 patients (42%) were still on the diet at the last follow-up.
Discussion
General data on the efficacy of the KD in pediatric epileptic patients have been remarkably consistent over the past decades, demonstrating cessation of all seizures with both structural or idiopathic etiology in up to 16% of patients, a greater than 90% reduction in seizure frequency in about 30-40% of patients and a greater than 50% reduction in seizures in up to 60% of patients [6] . Currently, few predictors for best response to KD have been found.
Our results showed that patients with malformations due to abnormal neural migration and patients with malformations due to abnormal post-migrational development had the best response, with a seizure reduction of > 50% in 7 (31.8%) and 11 (64.7%) patients, respectively. However, the group of malformations of abnormal neural proliferation was poorly represented, with only 6 patients. More importantly, a patient with microlissencephaly and a patient with polymicrogyria obtained seizure freedom. Electroencephalographic improvements were registered in 44% of patients. Since the majority of our patients had very severe encephalopathy and were not candidates for surgery, these results led to an improvement in the quality of life of both patients and their families. Our results are in line with those found in literature: the study of Jung et al. [7] showed a positive result among those with focal cortical dysplasia and the study of Stainman et al. [2] described seizure reduction > 50% in 54% of patients and no seizure freedom after 6 months of KD treatment.
In terms of epilepsy syndrome, KD appears to be a promising therapy for ESES patients with structural etiology as observed among our 5 patients. Among the latter, the two patients with unilateral polymicrogyria had the best response with >50% seizure reduction. This is congruent with the study of Reyes et al. [8] where KD was used effectively in ESES with structural etiology.
Starting KD at an earlier time respect to epilepsy onset appeared to be a positive predictive factor in only a small number of studies. We did not find a positive correlation between an early diet introduction(within 36 months of seizure onset) and seizure reduction associated with the KD. But it must be emphasized that the population analyzed was quite small.
Mechanisms underlying seizure protection conferred by KD are still poorly defined, as well as the ultimate underlying reason for specific cortical malformation as epileptogenic focus. However, possible mechanisms where KD might be effective among epileptic patients with structural abnormalities should be considered.
When coping with MCD, morphological and functional signs of dismaturity should be displayed: an unexpected finding in pediatric cortical dysplasia, for instance, was that GABA activity was not reduced. One hypothesis is that inhibiting the mammalian target of rapamycin (mTOR) pathway could be more effective in modifying epileptic activity in these patients [9] ,: the effect of KD on this pathway has been investigated and results show that KD could have an inhibitory effect on the kainate model of epilepsy [10] , Moreover, epilepsy secondary to MCD often manifests at an early age and during this time brain maturity is delayed. Hence, immature cerebral cortex could use ketone bodies more effectively than glucose as a substrate [11] . This could lead to immature brain experiencing faster ketone bodies' transport rates than mature brain [12] .
Our study includes the following limits: the sample size was small and there was a considerable difference in the number of patients in each group as well as in the time of follow up. Nevertheless, the beneficial effect of the treatment was observed after just three months.
A larger case-series study would be crucial to better evaluate the potential of KD treatment for epilepsy secondary to MCD.
Furthermore, a search for positive predictive factors of response other than seizure reduction could be helpful. Table 2 Response Rate on Ketogenic Diet in Terms of Seizure Frequency Reduction, and Reactivity changes at 1 SPAZIO month of diet initiation(T1), 3 months (T2) and last follow up (T3) (N = 45). GROUP 1* (n = 6) GROUP 2** (n = 22) GROUP 3** (n = 17) TOTAL POPULATION (N = 45)   T1  T2  T3  T1  T2  T3  T1  T2  T3  T1  T2 
33.3% (2) 33.3% (2) 36.4% (8) 45.5% (10) 31.8% (7) 47.1% (8) 52.9% (9) 64.7% (11) 40% (18) 46.7% (21) 44.4% (20) <50% reduction 33.3% (2) 16.7% (1) 16.7% (1) 40.9% (9) 31.8% (7) 54.6% (12) 29.4% (5) 29.4% (5) 17.6%
35.6% (16) 28.9% (13) 35.6% (16) no reduction 33.3% (2) 33.3% (2) 33,3% b (2) 22.7% (5) 18.2% (4) 13.6%
17.6%
11.8% (2) 11.8% (2) 22.2% (10) 17.8% (8) 15.5%
Reactivity unchanged 66.7% (4)
40.9% (9) 31.8% (7) 36.4% 
50% (11) 50% (11) 45.5% (10) 41.2% (7) 41.2% (7) 41.2% (7) 42.2% Time Interval of Follow-up: T1-at 3rd month; T2 À at 6th month; T3-at last follow-up. Efficacy of Ketogenic diet was assessed in terms of seizure reduction compared to time 0 (time of starting the diet): seizure freedom, seizure reduction of 50%, less of 50% seizure reduction, no change in seizure frequency. Reactivity changes were registered on the basis of parent's reports and clinical observation according to attentiveness and to environment participation improvement.
Conclusions
The results of this study showed that KD might be effective in seizure frequency reduction and quality of life improvement in patients with drug-resistant epilepsy secondary to MCD, but seizure freedom is rarely achieved. Once the viability of surgery is excluded, KD utilization should be considered for DRE* due to MCD.
Moreover, the search for a specific structural lesion that could most benefit KD, including possible genetic studies, could optimize the timing of KD initiation.
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